Molecular Partners AGMLLCF 25 Debt-to-Equity is 0.05 as of Mar. 2026, which is 150% above its 10-year median of 0.02. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 965 Biotechnology companies, Molecular Partners AG ranks better than 72.02% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Molecular Partners AG's Debt-to-Equity or its related term are showing as below:
MLLCF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 0.07
Current: 0.05
During the past 13 years, the highest Debt-to-Equity Ratio of Molecular Partners AG was 0.07. The lowest was 0.02. And the median was 0.02.
MLLCF's Debt-to-Equity is ranked better than 72.02% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs MLLCF: 0.05
Molecular Partners AG (OTCPK:MLLCF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Molecular Partners AG Debt-to-Equity Related Terms
Molecular Partners AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Molecular Partners AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Debt-to-Equity of 0.05 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Molecular Partners AG and its competitors. This is 150% above median its historical median of 0.02. Over the past decade, Molecular Partners AG's Debt-to-Equity has ranged from 0.02 to 0.07. According to the industry distribution chart, Molecular Partners AG ranks #270 out of 965 companies in the Biotechnology industry, placing it in the top 28%.
Is Molecular Partners AG's Debt-to-Equity too high?
Molecular Partners AG's current Debt-to-Equity of 0.05 is 150% above median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.07. The Biotechnology industry median Debt-to-Equity is 0.16. Molecular Partners AG's value of 0.05 is 68.8% below this industry median. Based on the distribution chart, Molecular Partners AG ranks #270 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #270 out of 965 companies for Debt-to-Equity. This puts Molecular Partners AG in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Molecular Partners AG's value of 0.05 is 68.8% below this benchmark. Historically, Molecular Partners AG's own Debt-to-Equity has ranged from 0.02 to 0.07 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.16, Molecular Partners AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Debt-to-Equity is 0.05, which is 150% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.80 — trading 645.1% above its estimated fair value. The current Debt-to-Equity is 0.05, which is 150% above median its 10-year median of 0.02 and 68.8% below the Biotechnology industry median of 0.16. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Debt-to-Equity is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.80 is trading 645.1% above its estimated GF Value™ of $0.51.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Debt-to-Equity: 0.05 (150% above median its 10-year median of 0.02)
GF Value™: $0.51 vs. price of $3.80 (645.1% above fair value)
Industry Position: 68.8% below the Biotechnology median (#270 of 965)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
